

Please place a plus sign (+) inside this box.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

Complete if Known

| | |
|------------------------|-------------------------|
| Application Number | 10/725,373 |
| Filing Date | December 3, 2003 |
| First Named Inventor | Jeffrey SCHLOM et al. |
| Group Art Unit | 1644 |
| Examiner Name | Marianne Neale DiBriano |
| Attorney Docket Number | 38163-0197 |

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered


12/9/0x

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box  PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|--|--------------------------|----------------------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/725,373 |
| | | Filing Date | December 3, 2003 |
| | | First Named Inventor | Jeffrey SCHLOM et al. |
| | | Group Art Unit | 1644 |
| | | Examiner Name | Marianne Man DiBriano |
| Sheet 2 of 2 | | Attorney Docket Number | 38163-0197 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| MO | B02 | CHEN, Y., et al., Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonist and TCR antagonism with or without partial activation. J. Immunol., 157: 3783-3790 (1996). | |
| MO | B03 | JAMESON, S.C., et al., T cell receptor antagonists and partial agonists. Immunity, 2:1-11 (1995). | |
| MO | B04 | TSANG, K.Y., et al., Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87:982-990 (1995). | |
| MO | B05 | ZAREMBA, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Research. 57:4570-4577 (1997). | |
| MO | B06 | RUPPERT J. et al., "Class I MHC-Peptide Interaction: Structural and Functional Aspects", Behring Institute: Mitteilungen, July 1, 1994, p. 48-60, no. 94, XP000604845 | |
| MO | B07 | DENIS HUDRISIER et al., "Binding of Viral Antigens to Major Histocompatibility Complex Class I H-2D ^b Molecules Is Controlled by Dominant Negative Elements at Peptide Non-anchor Residues", The Journal of Biological Chemistry", 1996, pp. 17829-17836, Vol. 271, No. 30 | |
| MO | A08 | LUIS JAVIER SIGAL et al., "Role of Non-Anchor Residues of D ^b -Restricted Peptides in Class I Binding and TCR Triggering", Molecular Immunology, 1996, pp. 1323-1333, Vol. 33, No. 17/18 | |
| MO | A09 | LUIS J. SIGAL et al., "D ^b -Binding Peptides from Influenza Virus: Effect of Non-Anchor Residues on Stability and Immunodominance", Molecular Immunology, 1995, pp. 623-632, Vol. 32, No. 9 | |
| MO | A10 | CATARINA E. HIOE et al., "Alterations of a Dominant Epitope of Lymphocytic Choriomeningitis Virus Which Affect Class I Binding and Cytotoxic T Cell Recognition", Molecular Immunology, 1995, pp. 725-731, Vol. 32, No. 10 | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--------------------------|-----------------|---------|
| Examiner Signature | <i>Marianne DiBriano</i> | Date Considered | 12/9/05 |
|--------------------|--------------------------|-----------------|---------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.